| Literature DB >> 32755608 |
Denis P Blondin1, Soren Nielsen2, Eline N Kuipers3, Mai C Severinsen2, Verena H Jensen2, Stéphanie Miard4, Naja Z Jespersen2, Sander Kooijman3, Mariëtte R Boon3, Mélanie Fortin5, Serge Phoenix6, Frédérique Frisch5, Brigitte Guérin7, Éric E Turcotte7, François Haman8, Denis Richard4, Frédéric Picard4, Patrick C N Rensen3, Camilla Scheele9, André C Carpentier10.
Abstract
Stimulation of brown adipose tissue (BAT) thermogenesis in humans has emerged as an attractive target to improve metabolic health. Pharmacological stimulations targeting the β3-adrenergic receptor (β3-AR), the adrenergic receptor believed to mediate BAT thermogenesis, have historically performed poorly in human clinical trials. Here we report that, in contrast to rodents, human BAT thermogenesis is not mediated by the stimulation of β3-AR. Oral administration of the β3-AR agonist mirabegron only elicited increases in BAT thermogenesis when ingested at the maximal allowable dose. This led to off-target binding to β1-AR and β2-AR, thereby increasing cardiovascular responses and white adipose tissue lipolysis, respectively. ADRB2 was co-expressed with UCP1 in human brown adipocytes. Pharmacological stimulation and inhibition of the β2-AR as well as knockdown of ADRB1, ADRB2, or ADRB3 in human brown adipocytes all confirmed that BAT lipolysis and thermogenesis occur through β2-AR signaling in humans (ClinicalTrials.govNCT02811289).Entities:
Keywords: brown adipocyte; brown adipose tissue; cold-induced thermogenesis; energy metabolism; mirabegron; positron emission tomography; β(2)-adrenergic receptor
Year: 2020 PMID: 32755608 DOI: 10.1016/j.cmet.2020.07.005
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287